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Thermal ablation using radiofrequency is a new, minimally invasive modality employed as an alternative to surgery in 
patients with benign thyroid nodules and recurrent thyroid cancers. The Task Force Committee of the Korean Society of 
Thyroid Radiology has developed recommendations for the optimal use of radiofrequency ablation for thyroid nodules. These 
recommendations are based on a comprehensive analysis of the current literature, the results of multicenter studies, and 
expert consensus.
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INTRODUCTION
Thermal ablation using radiofrequency (RF) is a new, 
minimally invasive modality that may be an alternative 
to surgery in patients with benign thyroid nodules. RF 
ablation has shown efficacy and safety in the treatment 
of thyroid nodules (1-8). In 2009, the Korean Society of 
Thyroid Radiology (KSThR), an organization of thyroid 
radiologists in Korea primarily involved in the diagnosis 
and treatment of thyroid nodules, proposed the first set of 
recommendations for RF ablation of thyroid nodules (9). 
These recommendations were formulated by an organized 
task force committee that included specialists of thyroid 
RF ablation in Korea. These recommendations included only 
patient selection and the efficacy of RF ablation. Because 
new information has become available since 2009 from 
clinical studies of RF ablation in patients with benign 
thyroid nodules and recurrent thyroid cancers, the task 
force committee members suggested the need to revise 
earlier recommendations. The KSThR therefore organized 
a committee to revise these earlier recommendations, and 
this committee prepared recommendations for RF ablation 
of thyroid nodules and recurrent thyroid cancers on June 3, 
2011. The revised recommendations include sections dealing 
with indications for RF ablation, pre-procedural evaluations, 
RF ablation procedures, post-procedural monitoring, 
efficacy, and safety. A PubMed Medline search was 
performed with the keywords ‘‘radiofrequency’’ and ‘‘thyroid’’ 
up to October 2011. Because there are only a few controlled 
clinical studies (6, 10) of RF ablation, the recommendations 
regarding some issues are based on expert opinions. This 
limitation needs to be overcome in the future by further 
investigations.
The goal of these recommendations is to provide the best 
scientific evidence available and a consensus expert opinion 
regarding the use of RF ablation of the thyroid in clinical 
practice.
INDICATIONS
Radiofrequency ablation can be used to treat both benign 
thyroid nodules and inoperable, recurrent thyroid cancers 
in the operation bed and lymph nodes (1-8, 10-17). The 
KSThR does not recommend thyroid RF ablation for follicular 
neoplasms or primary thyroid cancers because there is no 
evidence of treatment benefit by RF ablation in follicular 
neoplasms or primary thyroid cancers (2, 18). Caution 
should be taken in regard to the use of thyroid RF ablation 
in pregnant women, patients with serious heart problems, 
and those with contralateral vocal cord palsy (19-23).
1. Benign thyroid nodules
Indications for RF ablation of benign thyroid nodules 
include patients with nodule-related clinical problems (2-5, 
12, 14):
1) Symptom (neck pain, dysphasia, foreign body sensation, 
discomfort, and cough) score can be self-measured by 
patients using a 10 cm visual analogue scale (grade 0-10) (6, 
7, 24)
2) Cosmetic score (1, 4, 6, 7, 24) can be measured by a 
physician (6-8). Cosmetic score (1, no palpable mass; 2, no 
cosmetic problem but palpable mass; 3, a cosmetic problem 
on swallowing only; and 4, a readily detected cosmetic 
problem)
3) Patients with autonomously functioning thyroid 
nodules (AFTN) causing problems related to thyrotoxicosis 
(1, 4, 5, 12, 25-29)
Patients with nodules with a maximum diameter > 2 
cm that continue to grow, may be considered for thyroid 
RF ablation based on symptoms and clinical concerns. We 
recommend that patients with cystic thyroid nodules that 
re-grow after simple aspiration should be treated first with 
ethanol ablation (EA) rather than RF ablation (7, 8, 24, 30, 
31). The efficacy and complications were similar in both 
EA and RF ablation groups, but the number of treatment 
sessions was fewer in the EA group. In addition, EA is a 
simple and less expensive procedure (8).
2. Recurrent thyroid cancers (operation bed and lymph 
nodes)
Surgery is a standard treatment for recurrent thyroid 
cancers, followed by radioactive iodine and thyroid hormone 
therapy. RF ablation, however, can be used in patients at 
high surgical risk and in patients who refuse to undergo 
repeated surgery (11, 13, 16, 17).
PRE-PROCEDURAL EVALUATIONS
Prior to treatment of benign thyroid nodules (Table 1), 
thyroid nodules should be confirmed as benign on at least 
two separate ultrasound (US)-guided fine needle aspiration 
and/or core needle biopsy (32, 33). Caution should be 
taken in performing the RF ablation of thyroid nodules with 
malignant US features, even though there are benign results 
on fine needle aspiration or core needle biopsy (2, 34-40). 
Symptom and cosmetic scores should be determined before 
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RF ablation for comparison with follow-up data (3, 6-8, 12, 
24, 41).
Ultrasound examination is important to characterize 
the nodule and evaluate the critical surrounding anatomic 
structures (2). The size, characteristics, proportion of solid 
component, and internal vascularity of each nodule should 
be evaluated. Three orthogonal nodule diameters, including 
the largest diameter, should be measured by US, and nodule 
volume could be calculated using the equation: V = πabc/6, 
where V is the volume, a is the maximum diameter, and b 
and c are the other two perpendicular diameters. (2, 6, 8)
Laboratory tests usually include a complete blood count, 
a blood coagulation battery, as well as measurements of 
thyrotrophin, thyroid hormones, thyroid auto-antibodies, 
and calcitonin concentrations (6, 42). If any serum 
concentrations are abnormal, RF ablation should be 
performed only after performing procedures to correct these 
abnormal test results. When platelets and blood coagulation 
test results are abnormal, we should document whether a 
patient has taken medications such as anti-platelets and 
anticoagulants or has any disease causing coagulopathy. 
When serum concentration of thyrotropin is elevated, 
further tests should be performed to document whether 
a patient has hypothyroidism. When serum concentration 
of thyrotrophin is reduced, we should document whether 
a patient is being treated with thyroid hormones or has 
hyperthyroidism. If a thyroid hormone was prescribed to 
control the growth of thyroid nodules, we recommend that 
this drug be stopped before RF ablation. 
If hyperthyroidism or AFTN is suggested, a technetium 
99mTc pertechnetate or a 123I thyroid scan may be helpful 
for diagnosis (5, 12, 43). When serum concentration of 
calcitonin is elevated, an additional thorough assessment 
of thyroid nodules is necessary before RF ablation therapy 
because high serum calcitonin may suggest a medullary 
carcinoma (25, 29, 44). If the concentrations of thyroid 
antibodies are elevated before ablation, patients should 
be told about the possibility of hypothyroidism after 
the procedure. It remains unclear, however, whether 
hypothyroidism is caused by RF ablation or thyroid 
antibodies (12, 42, 45). CT or MRI examinations may help 
evaluate intrathoracic thyroid nodules.
Prior to treatment of recurrent thyroid cancers (Table 1), 
tumor recurrence should be confirmed by US-guided fine 
needle aspiration (16). US-guided fine needle aspiration 
cytology and measurements of washout thyroglobulin 
(Tg) concentration are methods diagnostic for recurrent 
thyroid cancers (16, 46-50). US examination is important 
to evaluate the recurred tumor and the critical surrounding 
structures. The size, volume, and vascularity of the 
recurred tumor should be assessed by US (11, 13, 16, 
17). Laboratory tests usually include a complete blood 
count, a blood coagulation battery, and measurements of 
thyrotrophin, thyroid hormones, thyroglobulin, and anti-
thyroglobulin antibody (6, 11, 13, 16, 17, 42). A neck CT 
may be selectively used for the evaluation of a recurrent 
tumor prior to RF ablation.
Informed consent forms should include the following 
content (2):
1) Ablated thyroid nodules decrease slowly in size for 
several months to years 
2) Number of expected treatment sessions
3) Possibility of regrowth of the treated nodule and the 
need for additional treatment
4) Patients may experience various degrees of pain during 
the ablation 
5) Complications of RF ablation
6) Patients should inform the physician about their 
Table 1. Preprocedural Check List for RF Ablation
Benign Thyroid Nodule Recurrent Thyroid Cancer
Benign histocytologic diagnosis (at least two times) Histocytologic diagnosis of recurrence
US features of nodule and neck US features of critical surrounding structures 
Nodule volume Tumor volume 
Symptom score
Cosmetic score
Laboratory tests 
Laboratory tests 
  (serum thyroglobulin, anti-thyroglobulin antibody)
CT or MRI*
Technetium 99mTc pertechnetate or a 123I thyroid scan†
CT*
Note.— *Selectively indicated, †Indicated for AFTN. RF = radiofrequency, US = ultrasound
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history of thyroid surgery, the side effects of any drugs they 
are taking, and whether they are taking drugs such as anti-
platelets, anticoagulants and thyroid hormones. 
7) Further observation or admission may be required after 
RF ablation, depending on the patients’ condition after 
ablation.
Patients taking drugs associated with a bleeding 
tendency should be told to discontinue those drugs before 
RF ablation: 7-10 days for aspirin or clopidogrel, 3-5 days 
for warfarin and 4-6 hours for heparin. Patients can take 
heparin 2-6 hours after RF ablation, warfarin on the night 
after the procedure and aspirin (or clopidogrel) the next 
day (51). However, physicians should compare the benefits 
of RF ablation with its potential complications related to 
the interruption of these drugs. If required, patients should 
consider changing warfarin to heparin, which has a shorter 
half-life (1-2 hours) (51). Moreover, patients should fast for 
at least 6 hours before each procedure. We recommend that 
a venous line be installed before the procedure for drug 
delivery.
PROCEDURE, MONITORING AND FOLLOW-UP
We recommend that RF ablation be performed using a 
‘trans-isthmic approach’ and a ‘moving shot technique’ 
under local anesthesia because these techniques are useful 
for the safe and effective RF ablation procedure (2, 6, 12, 
41, 52). A modified, straight, internally cooled electrode is 
suitable for use in the moving shot technique (12, 41). 
Physicians should monitor blood pressure, pulse rate 
and the voice of each patient by regular conversations 
during the procedure. If a voice change is suspected, the 
physician should stop the procedure immediately (41, 
53). Although pain was found to be the most common 
complaints during RF ablation, it was relieved rapidly when 
the generator output was reduced or turned off (2, 6, 12, 
41, 53). Painkillers and sedatives can relieve pain during 
the ablation (1), but we do not recommend the painkillers 
or sedatives during the ablation because the early detection 
of complications is impossible in patients under deep 
sedation, which disturbs communication.
Ultrasound monitoring is important for detecting 
hemorrhage (2, 41). If a hematoma is too large or pain is 
too severe due to hemorrhage, manual compression may be 
helpful, allowing the procedure to continue. Hematomas 
usually disappear completely within 2 weeks. When a large 
hematoma develops, the RF procedure should be delayed for 
1-2 weeks (41). 
Patient condition should be monitored after the procedure 
(2, 41). Patients with severe pain, edema, skin burn, 
vomiting, dyspnea, or voice change should be continuously 
monitored. The decision to admit a patient should be at the 
discretion of each physician (42).
During the follow-up periods, painkillers and steroids 
can be used to relieve symptoms (42). Color-Doppler US is 
a primary imaging modality during follow-up. In addition, 
patients can be monitored by CT, MRI, thyroid scans, 
and thyroid function tests. Color-Doppler US is useful for 
detecting any undertreated or regrowing portion of the 
ablated nodules (2, 7, 12, 41). We recommend that patients 
be followed-up at 1-2, 6 and 12 months after RF ablation, 
as well as every 6-12 months thereafter, depending on the 
status of the treated nodules (2, 6, 12, 41). Additional 
treatments may be indicated in patients with incompletely 
resolved clinical concerns or if a viable growing portion of 
the nodule is detected on US (2, 41, 52).
EFFICACY
Efficacy of RF ablation for benign thyroid nodules can 
be evaluated by symptom score, cosmetic score, % volume 
reduction ([initial volume - final volume] x 100/initial 
volume) (2, 6, 12), and therapeutic success rate (volume 
reduction > 50%) (8). Color-Doppler US is helpful for the 
evaluation of presence of vascularity within the ablated 
nodule, which suggests a possible undertreated area of 
a nodule (41, 52). For AFTN, we additionally recommend 
evaluation with a thyroid scan, serum thyroid hormone, and 
thyrotrophin concentration (1, 4, 12). The efficacy of RF 
ablation for recurrent thyroid cancers can be evaluated by 
% volume reduction and serum thyroglobulin concentrations 
(11, 13, 16, 17). 
Radiofrequency ablation cannot remove thyroid nodules 
immediately; rather, it induces the necrosis and involution 
of thyroid nodules, resulting in volume reduction and 
improvements in clinical symptoms, with the efficacy 
of RF ablation similar to that of thyroid surgery (2-4). 
Hyperthyroidism caused by AFTN can be cured or improved 
by RF ablation (1, 4, 12). Although most patients have 
shown improvements after a single session of RF ablation, 
others may require several sessions to achieve complete 
ablation (2-4, 6, 12, 14). The reduction in nodule volume 
after RF ablation has been found to range from 33-58% at 
one month and from 51% to 92% at six months (1-4, 6, 
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7, 12, 54). Laser ablation has been used for the treatment 
of benign thyroid nodules (18, 26, 42, 55-63). When we 
compared the efficacy of two treatment tools, the efficacy 
of RF ablation appears to be slightly superior to that of 
laser ablation (10, 41, 54). RF ablation can be used for 
locoregional control of cancer or improvement of cancer 
related symptoms in patients with recurrent thyroid cancer 
who have a high surgical risk and refuse repeated surgery 
(11, 13, 17). RF ablation of recurrent thyroid cancers in 
the neck resulted in a mean volume reduction of 56% to 
93% (13, 16), with 42% to 58% of nodules completely 
disappearing (11, 16, 17), 64% of patients experiencing 
symptom improvement (13), and serum thyroglobulin 
concentration decreasing (11, 13, 16, 17). However, long-
term follow-up data has not been published yet.
SAFETY
Physicians who perform thyroid RF ablation should 
understand the broad spectrum of complications and the 
steps they can take to prevent or minimize complications 
and sequelae (52, 53). Reported complications of thyroid RF 
ablation include pain, hemorrhage, voice change, skin burn, 
hypothyroidism, hyperthyroidism, infection and nodule 
rupture (1-4, 6, 9, 12). RF ablation does not require general 
anesthesia, does not induce scarring of the neck, and when 
performed by well-trained physicians, is associated with a 
low complication rate (1-6).
In November 2008, the KSThR organized a task force to 
evaluate the complications and side effects of thyroid RF 
ablation of benign nonfunctioning thyroid nodules (53). 
This task force collected data on complications from 13 
hospitals in Korea and evaluated them according to the 
guidelines of the Society of Interventional Radiology (65, 
66). These complications and side effects are listed in Table 
2 (53). Complications were reported in 48 patients (3.3%) 
and major complications in 20 (1.4%). Among the reported 
sequelae are hypothyroidism in one patient and abscess 
formation and tumor rupture in one (53). During the 
ablation, most patients complain of various degrees of pain 
in the neck and/or radiating to the head, ear, shoulders, 
chest, back, or teeth. However, pain decreases rapidly when 
the generator output is reduced or turned off (2, 6, 41, 53). 
We recommend that patients may be prescribed painkillers 
for 2-3 days to reduce post-procedural pain (41).
Voice change is a major complication of RF ablation, 
caused by damage to the recurrent laryngeal or vagus 
nerve (67, 68). In most cases, voice change is detected 
during or immediately after ablation. Voice changes are 
usually transient, with most patients recovering within 3 
months (41, 53). To prevent voice change, we recommend 
that RF ablation should be performed using the ‘trans-
isthmic approach and the ‘moving shot technique’. Using 
these techniques, unit-by-unit ablation of conceptual 
ablation units by moving the electrode and undertreatment 
of the danger triangle (i.e. the area of the thyroid nodule 
adjacent to the recurrent laryngeal nerve), may minimize 
voice changes (41, 52, 53). The cervical portion of the 
vagus nerve is located within the carotid sheath, usually 
between the common carotid artery and internal jugular 
vein, however a bulging large thyroid nodule may alter the 
location of the vagus nerve, making it closer to the thyroid 
nodule (67-70). We recommend checking the location of the 
vagus nerve before RF ablation. There is a potential risk of a 
sympathetic ganglion damage. If extrathyroidal penetration 
of a electrode is not detected during the ablation 
procedure, it may induce ablation injury of sympathetic 
ganglion because it is located posterior to common carotid 
artery near the thyroid gland. To avoid this complication, 
continuous and cautious US-guided tracing of the electrode 
tip is mandatory during the RF ablation.
Hematomas, resulting from electrode-induced mechanical 
Table 2. Complications and Side Effects of Thyroid RF 
Ablation from Multicenter Study of Korean Society of 
Thyroid Radiology (53)
Complications Number of Complications (%)
Major complications 20 (1.4)
Voice change 15 (1.02)
Nodule rupture 2 (0.14)
Nodule rupture with abscess* 1 (0.07)
Hypothyroidism* 1 (0.07)
Brachial plexus injury 1 (0.07)
Minor complications 28 (1.92)
Hematoma 15 (1.02)
Vomiting 9 (0.62)
Skin burn 4 (0.27)
Side effects 46 (3.15)
Pain 38 (2.6)
Vasovagal reaction 5 (0.34)
Coughing 3 (0.21)
Note.— Number in parentheses is percentage of complications 
of all patients. *Complications with remaining sequela. RF = 
radiofrequency
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injury, can occur in the perithyroidal, supcapsular, and 
intranodular locations (53). Hematomas can usually be 
controlled by mild compression of the neck for several 
minutes, with most hematomas disappearing within 1 or 
2 weeks (41). Since serious hematomas may compress the 
airways, close observation is recommended during and after 
procedure. Serious hemorrhage may be prevented by careful 
monitoring of the electrode tip (41).
Transient thyrotoxicosis may occur after RF ablation, 
but it is usually normalized within one month (2). 
Hypothyroidism has been reported in patients with 
nonfunctioning thyroid nodules and those with AFTN (12, 
53). Consequently, thyroid function tests are recommended 
during follow-up for these patients (2, 3, 12, 42, 53). To 
prevent an infection or abscess, the puncture site should 
be sterilized before RF ablation and prophylactic antibiotics 
can be used. 
Thyroid nodule rupture after RF ablation may be suspected 
in patients complaining of sudden neck bulging and pain 
at the treatment site (41, 53, 71). Prior to nodule rupture, 
the ablated thyroid nodule gradually decreases in size. US 
examination usually shows a breakdown of the anterior 
thyroid capsule and the formation of a new nodule in the 
anterior neck. Delayed sudden perinodular hemorrhage 
might be a cause of nodule rupture. Spontaneous 
improvement without treatment is possible, but surgery is 
required when an abscess forms (41, 53, 71). 
During thyroid RF ablation, skin burns have been reported 
only at the electrode puncture site (3, 13, 53). Application 
of an ice bag during the ablation may prevent skin burns 
at the electrode puncture site. The risk of burns at the 
pad attachment site is relatively low, because RF energy 
is lower in the thyroid than in the liver (53). Nausea and 
vasovagal reflection may be caused by severe tension, pain, 
or hypersensitivity to lidocaine (53).
Life-threatening complications, including injury to the 
trachea (72) and heart attack (19, 20, 22, 23, 73), have 
been reported in patients undergoing RF ablation of tumors 
other than those of the thyroid gland. However, these 
complications, as well as esophageal rupture, have not 
been reported yet. Coughing can be induced by thermal 
propagation to the trachea and is managed by stopping 
the ablation (41, 53). To prevent thermal injury to the 
esophagus, patients should be asked to swallow cold water 
during the ablation of a conceptual unit adjacent to the 
esophagus (19, 21, 41, 53). 
To prevent life-threatening complications, the operators 
should strictly trace the electrode tip during the procedure, 
and should have knowledge of the neck’s anatomy and 
experience of an image-guided intervention. 
CONCLUSION
Thyroid RF ablation is an effective and safe treatment 
modality in patients with benign thyroid nodules. RF 
ablation may be as effective as surgery if it is performed by 
experienced physicians in optimally selected patients. RF 
ablation may also have an effective complementary role in 
the management of recurrent thyroid cancers. 
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